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Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate
(FTC/TDF) is a novel HIV prevention strategy. Suboptimal PrEP adherence and HIV infec-
tion creates an opportunity for continued antiretroviral drug activity during undiagnosed
infection. We previously showed that macaques infected with SHIV during PrEP with FTC/
TDF display reduced acute plasma viremias and limited virus diversity. We investigated the
effect of PrEP on acute SHIV DNA dynamics and on the size of the persistent virus reser-
voir in lymphoid tissues.
Design
Cell-associated SHIV DNA levels in PBMCs were measured in 8 macaques infected during
PrEP with FTC/TDF or single-agent TAF and was compared to those seen in untreated
infections (n = 10). PrEP breakthrough infections continued treatment with 1–2 weekly drug
doses to model suboptimal drug exposure during undiagnosed HIV infection in humans.
SHIV DNA was also measured in lymphoid tissues collected from FTC/TDF PrEP break-
throughs after 1 year of infection.
Results
Compared to untreated controls, PrEP infections had reduced plasma RNA viremias both
at peak and throughout weeks 1–12 (p<0.005). SHIV DNA levels were also reduced at
peak and during the first 12 weeks of infection (p<0.043) but not throughout weeks 12–20.
At 1 year, SHIV DNA reservoirs in lymphoid tissues were similar in size among macaques
that received PrEP or placebo.
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Conclusions
Antiviral drug activity due to PrEP limits acute SHIV replication but has only a transient
effect on cell-associated SHIV DNA levels. Our model suggests that suboptimal drug expo-
sure in persons that are taking PrEP and become infected with HIV may not be sufficient to
reduce the pool of HIV-infected cells, and that treatment intensification may be needed to
sustain potential virological benefits from the PrEP regimen.
Introduction
Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) in combina-
tion with emtricitabine (FTC) is an effective strategy to prevent HIV infection. In clinical trials,
the level of HIV protection by PrEP was strongly correlated with drug adherence [1]. In the
Partners PrEP trial among heterosexualmen and women, plasma tenofovir (TFV) concentra-
tions consistent with daily FTC/TDF dosing were associated with a protective effect of 91% [2].
A modelling study combining data from the iPrEX trial in men or transgender women who
have sex with men and the STRAND study with directly observeddosing predictedHIV reduc-
tions of 76%, 96% and 99% if FTC/TDF were dosed at 2, 4, and 7 doses per week [3]. Very low
adherence was one of the reasons why two other clinical trials among young African women
(VOICE and FEM-PrEP) failed to show any efficacyof either daily TDF or FTC/TDF [4, 5].
Across trials, analyses of participants with detectable drug levels demonstrated higher efficacy
than analyses that did not include objective adherencemeasurements.
Suboptimal PrEP adherence and HIV infection creates an opportunity for continued antire-
troviral (ARV) drug activity during undiagnosed infection. Transient drug activity between
HIV infection and diagnosis may potentially reduce virus replication. In macaques, infection
with a chimeric simian HIV (SHIV) during concurrent PrEP failure with FTC/TDF resulted in
blunted acute plasma viremias documented sequentially by weekly sampling following first
viral RNA detection [6, 7]. In addition, a geneticallymore homogeneous virus populations was
found in these macaques compared to untreated infections [8]. This virological outcome also
resulted in a better preservation of immune responses [9]. Limited sampling in human PrEP
studies may not allow the demonstration of blunted viremias in persons who fail PrEP, how-
ever, in a small analysis of seroconverters from the TDF2 human PrEP trial, HIV sequences
from participants with measurable FTC and TFV in plasma at their seroconversion visit were
found to be more homogeneous than those from participants who had no detectable FTC or
TFV or who were not taking PrEP [10]. Although not definitive, these findings suggested that
transient drug activity during PrEP breakthrough infectionwith either HIV or SHIV can
decrease virus replication and slow viral evolution.
Emerging evidence shows that early ARV treatment has greater impact in limiting HIV or
SIV reservoirs than later treatment but the long-term effect on virus control or total reservoir
size is not fully clear especially when ARV treatment is stopped [11–14]. Here we used a well-
established SHIV PrEP model with well-definedPrEP regimens and durations of ARV treat-
ment to retrospectively investigate the impact of transient ARV exposuremaintained during
PrEP failure on the size of the cell-associated SHIV DNA reservoir. We first defined acute
SHIV DNA dynamics in PBMCs frommacaques that failed PrEP but continued receiving
ARV treatment with 1–2 weekly doses of FTC/TDF combination or the single agent tenofovir
alafenamide (TAF). We also investigated the long-term effects of PrEP on SHIV DNA pools by
measuring the size of DNA reservoirs in lymphoid tissues late in the infection after ARV treat-
ment was stopped.
PrEP and SHIV DNA Reservoirs
PLOS ONE | DOI:10.1371/journal.pone.0164821 November 2, 2016 2 / 13
Material and Methods
Ethics statement
All animal procedures were performed according to NIH guidelines and approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of the Centers for Disease Control and
Prevention (CDC).Macaques were housed at the CDC under the care of CDC veterinarians in
accordance with the Guide for the Care and Use of Laboratory Animals 8th Ed. All procedures
were performed under anesthesia (10 mg/kg ketamine or 2–6 mg/kg telazol; intramuscular),
and all efforts were made to minimize suffering, improve housing conditions, and to provide
enrichment opportunities. For housing, macaques were maintained in cages that met or
exceeded the minimum size requirements as stipulated in the Guide for the Care and Use of
Laboratory Animals [cage dimensions (inches): 30 (height) x 30 (width) x 30 (length)]. Steps
were taken to reduce animal suffering, which included providing enrichment opportunities
[e.g. cage features like swings/perches and objects for the macaques to manipulate], an assort-
ment of food selections like fruits, vegetables or seeds, suitable feedingmethods (foraging and
task-oriented), and humane interactions with caregivers and research staff. All animals have
access to clean, fresh water at all times. Commercial diets are specifically formulated to meet
vitamin C requirements. Prior to the initiation of virus inoculations, compatible macaques are
pair-housed. Once inoculations are initiated, the macaques are separated into single housing
(while permitting eye-contact) with a cage divider to prevent the possibility of SHIV transmis-
sion between the macaques. If one macaque remained uninfected during the course of a study,
the animal remained separated from other infectedmacaques, and was not be pair-housed
with an infectedmacaque during the follow-up period. Euthanasia of SHIV infectedmacaques
(n = 30 from studies in references [6, 7, 15, 16]) was accomplished in a humane manner (intra-
venous pentobarbital) by acceptable techniques as recommended by the American Veterinary
Medical Association Guidelines on Euthanasia, 2013, and in accordance with CDC-Atlanta
IACUC Policy on Euthanasia. The senior medical veterinarian and/or trained Comparative
Medicine Branch staff verified successful euthanasia by the lack of a heart beat and respiration.
Death was not used as a study endpoint.
Study population
A first cohort of macaques comprised animals enrolled in SHIV transmission studies as PrEP-
treated (n = 8) or controls (n = 10) [6, 7, 15]. These macaques were exposed rectally to
SHIV162P3 once a week for up to 14 weeks until infectionwas confirmedby molecular and sero-
logic testing [6, 7, 15]. The PrEP regimens consisted of two weekly doses of FTC/TDF (n = 6)
or one weekly dose of TAF (n = 2). The doses of FTC/TDF were given i) 24h before and 24h
after (-24/+24h) exposure, ii) 3 days before and 2h after (-3d/+2h) exposure, or iii) 7 days
before and 2h after (-7d/+2h) exposure [6]. The macaques infected during TAF PrEP received
a single dose of TAF 3 days before SHIV challenge (-3d) (Table 1) [15]. All 8 macaques with
PrEP breakthrough infections continued receiving drug for an average of 20 (11–28) weeks
after confirmed infection (Table 1).
A second cohort of 17 animals was used to investigate the long-term effect of early PrEP
treatment. We quantified cell-associated SHIV DNA in lymphoid tissues (mesenteric, axillary,
and inguinal lymph nodes) collected at necropsy approximately 1 year after confirmed infec-
tion. Of these animals, 9 were infected during intermittent PrEP with FTC/TDF and 8 were
untreated controls. Because of limited specimen availability, only a few animals from the first
cohort were included in this second analysis. We thus included additional animals that also
received FTC/TDF (1 or 2 doses everyweek) during the first months (median = 3.7) of
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infection [6, 16] (Table 3). Some of the macaques received a single dose of FTC/TDF or TAF
1–3 days prior to necropsy to measure drug penetration in rectal tissues [6, 15]. Lymph nodes
were collected 11 months (FTC/TDF) and 9 months (untreated controls) after confirmed infec-
tion and were processed as previously described [15]. Briefly, the tissues were homogenized
with a cell strainer (Fine mesh screens #20 and #10; company), washed several times with
RPMI 1640, and then carefully layered over Ficoll (Lymphocyte SeparationMedium (LSM, MP
Biomedicals, Aurora, OH)) to separate lymph nodemononuclear cells (LNMCs). LNMCs were
subsequently washed with RPMI 1640, counted, and stored in liquid nitrogen until use.
Quantitation of total SHIV DNA using a double-stranded primer (DSP)
assay
Rhesus macaque PBMCs were obtained from blood collected in BD Vacutainer1 CPT™ Cell
Preparation Tubes (CPT) containing sodiumheparin, resuspended in 200 ul of PBS, and stored
at -80°C until use. Genomic DNA was extracted from 200 ul aliquots using the QIAamp DNA
Mini and BloodMini kit (Qiagen) and resuspended in 100 ul of elution buffer. Total SHIV
DNA was quantified using a novel DSP assay coupled with co-amplification of RNase P gene
as internal PBMC control [17]. Amplification of SIV LTR (52 bp) was done using primers
pp119F (5’- Cy5/Quas670-GCCCTGGGAGGTTCTCTCCAGC-3’) and pp119R; (5’- GCAGG
GAACACCCAGGCTCTAC-3’) with quencher probe pp119Q (5’- GAGAACCTCCCAGGG
C-3’) with BHQ3 at the 3’ end. The final concentrations of primers and probe were 0.15uM
and 0.37uM, respectively. Co-amplification of RNase P (53 bp) was done using primers cp1116
(5’-FAM-CGGTGTTTGCAGACTTGGACGTG-3’) and cp1118 (5’- GCGCAGAGCCTTCAG
GTCAGA-3’) with quencher probe cp117 (5’- CCAAGTCTGCAAACACCG-3’) with BHQ2 at
the 3’ end. Final primers and probe concentrations for RNase P were 0.07uM and 0.19uM,
respectively. PCR amplification was done in an iQ5 Thermal Cycler (Bio-Rad) using the Quan-
tifast Multiplex Kit (Qiagen, Valencia, CA), and included activation of DNA polymerase at
95°C for 90 seconds followed by 42 cycles of 94°C for 1 second and 63°C for 20 seconds.
SHIV162P3 DNA and cellular RNase P were quantified using standard curves prepared by
serially diluting known copies of plasmid pVP1 and known amounts of macaque PBMCs,
respectively. Plasmid pVP1 contains the 50 portion of SIVmac239 from the 50 long terminal
repeat to a Sph I restriction site at nucleotide 6707, and was kindly provided by Dr. Cecilia
Cheng-Mayer (Aaron Diamond AIDS Research Center). The concentration of pVP1 was deter-
mined using a Nano Drop ND-1000 Spectrophotometer. Control PBMCs were prepared from
uninfected rhesus macaques and counted using the Guava Personal Cell Analysis (PCA) (Milli-
pore, Billerica,MA) system. S1 Fig shows that the DSP assay was able to consistently detect 10
copies of pVP1 plasmid (10/10 replicates positive). Assay reproducibility was investigated by
Table 1. Treatment dosing schedule and duration of treatment in PrEP breakthrough infections.
Treatment Number of weekly drug doses (dosing schedule) Duration of treatment after infection (months)
33053 FTC/TDF 2 (-24h/+24h) 7.0
FCW FTC/TDF 2 (-24h/+24h) 6.5
35838 FTC/TDF 2 (-24h/+24h) 6.0
DK40 FTC/TDF 2 (-3d/+2h) 5.0
34912 FTC/TDF 2 (-7d/+2h) 2.5
35032 FTC/TDF 2 (-7d/+2h) 5.3
DL2L TAF 1 (-3d) 2.8
1784 TAF 1 (-3d) 3.0
doi:10.1371/journal.pone.0164821.t001
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measuring variability in Ct values obtained in 16 separate dilution series prepared from
100,000 to 10 copies of pVP1 plasmid and from 300,000 to 30 rhesus PBMCs. The percentage
coefficient of variation (CV) was<4% for all different SIV DNA or PBMC inputs, demonstrat-
ing the robustness of the DSP assay in quantifying SHIV DNA and cellular RNase P with a
wide dynamic range (S1 Fig).
Quantification of SHIV RNA in plasma by one-step RT-PCR
SHIV162P3 RNA was quantified using a modification of an existing two-step RT-PCR assay
[18] that includes the use of a single RT-PCR reaction. Prior to RNA extraction, plasma sam-
ples (1 ml) were centrifuged at 43,000xg for 30 min to concentrate virus particles. RNA was
extracted from 140 ul virus pellets using the QIAamp Viral RNA kit (Qiagen) and eluted in
100 ul of elution buffer. To control for the efficiencyof extraction, a known amount of virus
particles (3×105) from an HIV-1CM240 virus stock (NIH Reference Reagent Program) was
added to each sample prior to RNA extraction.
Reverse transcription and PCR amplification of SHIV162P3 (gag) and HIV-1CM240 (env)
sequences was done using primers specific for SIVmac239 and HIV-1CM240, respectively. SIV gag
sequences were amplified using primers SIVp15f1 5’ GCCAAC AGG CTC AGA AAA TTT
AA 3’ and SIVp15r (5’ TCC TCA GTG TGT TTCACT TTC TCT TC 3’) with internal probe
P12P HEX (5’HEXAGC CTTTAT AAT(BHQ1) ACT GTC TGC GTC ATC TGG TGC
BHQ1 3’). Control HIV1CM240 was amplified using primers envE2f (5’ -GGA CAG GGCCAT
GTA AAAATG T -3’) and EnvE2r (5’ -TCT TCT GCT AGA CTG CCATTTAAC AG -3’)
with internal probe envEP (5’ FAM CAC ACA TGG AAT(BHQ1) TAA GCCAGT GRT ATC
MAC TCA BHQ1 3’). RT-PCR was done using the Superscript III one-step qRT-PCR kit (Invi-
trogen). The final concentrations of SIVmac239 primers and probe in the reaction were 200 nM.
Likewise, final concentrations of HIV-1CM240 primers and probe were 25nM and 100nM,
respectively. Cycling conditions were 10 minutes at 25°C, 60 minutes at 48°C, and 45 cycles of
95°C for 15 seconds and 60°C for 1 minute. The sensitivity of the RT-PCR assay is 50 RNA
copies/ml [19, 20].
Statistical analysis
Peak RNA and DNA levels, area under the curve (AUC) values for RNA and DNA during 5 or
20 weeks, and tissue DNA levels in PrEP breakthrough and placebo controls were compared
using a two-tailedWilcoxon rank-sum test. All analyses were done in GraphPad software (ver-
sion 5.04). The relationship between plasma RNA and cell-associatedDNA levels was deter-
mined using the Pearson correlation coefficient.
Results
Acute plasma RNA and cell-associated SHIV DNA dynamics in
macaques infected with SHIV162p3
We first defined acute plasma RNA and cell-associated SHIV DNA dynamics in rhesus
macaques (n = 10) infected rectally with SHIV162P3 without any PrEP intervention (Fig 1). The
median (range) peak SHIV RNA viremia was 7.5 (6.5–8.9) log10 RNA copies/ml with RNA levels
reaching a set-point at about 12 weeks of infection. Likewise, SHIV DNA levels peaked at 4.6
(2.8–5.3) log10 DNA copies/106 PBMCs and reached a set-point generally within 5 weeks of
infection.During these 5 weeks, DNA and RNA levels were highly correlated (Fig 1); Pearson
correlation coefficients (ρ) were indicative of a very strong correlation (between 0.93 and 0.98) in
8 macaques, and of a strong correlation (ρ = 0.57) in 1 animal. Thus, infection of macaques with
PrEP and SHIV DNA Reservoirs
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SHIV162p3 is characterized by a rapid control of plasma viremia within 12 weeks of infection and
the establishment of a DNA reservoir of about 102 to 104 SHIV DNA copies per 106 PBMCs.
Effect of PrEP on acute SHIV DNA dynamics
To investigate if PrEP can reduce the levels of cell-associated SHIV DNA in PBMCs, we com-
pared acute SHIV DNA dynamics between 8 PrEP breakthrough infections and the 10
untreated controls. These macaques were infected after a median of 5 (range = 2–14) rectal
challenges which was not different from the median of 3 (range = 1–10) rectal challenges
required to infect the 10 control animals (p = 0.099). Six of the 8 breakthrough infections
occurredduring intermittent PrEP with FTC/TDF (2 FTC/TDF doses per week) and two infec-
tions happened during intermittent PrEP with TAF (1 dose of TAF per week given 3 days prior
to virus challenges). The 8 PrEP breakthrough infections continued receiving intermittent anti-
retroviral treatment after confirmed infection for an average of 4.7 months (Table 1). Treat-
ment was originallymaintained to investigate risks of drug resistance emergence although
none of these animals developed the K65R or M184V mutation [6, 7, 15].
Fig 2 shows plasma RNA and cell-associated SHIV DNA levels in the 8 PrEP breakthroughs
infections and also highlights the length of treatment for each individual macaque. As seen in
Fig 1. Acute plasma RNA and cell-associated SHIV DNA levels in macaques infected with SHIV162P3. Time
0 denotes peak plasma viremia. SHIV RNA levels in plasma are shown in red. Cell-associated SHIV DNA levels in
PBMCs are shown in black. Small panels indicate the correlation between plasma RNA and DNA levels seen
between peak viremia and week 5. Pearson correlation coefficients are also shown.
doi:10.1371/journal.pone.0164821.g001
PrEP and SHIV DNA Reservoirs
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untreated SHIV162p3 infections, RNA and DNA levels were highly correlated during the first 5
weeks of infectionwith the only exception of macaques 35838 and 33053; Pearson correlation
coefficientswere very strong in 5 macaques (34912, 35032, DK40, DL2L, and 1784) and strong
in 1 animal (FCW).
Table 2 shows the median (range) values for SHIV RNA and DNA observed at peak, as well
as the overall levels of RNA and DNA seen throughout weeks 0–12 or 12–20 of infection
expressed as area under the curve (AUC) values. These intervals were selected to cover the acute
phase of infectionwith SHIV162p3 as well as the more chronic phase when viral RNA set-points
are reached (generally about 12 weeks; Fig 3 and [7]). Peak SHIVDNA levels in PBMCs in PrEP
breakthrough infections (3.6 log10 DNA copies/106 cells; range = 2.0–4.4) were significantly lower
than in untreated controls (4.6 log10; range = 2.8–5.3) (p = 0.043). DNA levels during the first 12
Fig 2. Acute plasma RNA and cell-associated SHIV DNA levels in macaques infected with SHIV162P3 while
receiving PrEP. Time 0 denotes peak plasma viremia. SHIV RNA levels in plasma are shown in red. Cell-
associated SHIV DNA levels in PBMCs are shown in black. The shaded areas denote the length of treatment
(green = FTC/TDF; orange = TAF). Small panels indicate the correlation between plasma RNA and DNA levels
seen between peak viremia and week 5. Pearson correlation coefficients are also shown.
doi:10.1371/journal.pone.0164821.g002
Table 2. SHIV162P3 plasma RNA and cell-associated DNA in PrEP breakthroughs and placebo infections.
PrEP breakthrough infections (n = 8) Placebo Infections (n = 10)
SHIV DNA in PBMCs
Peak 3.6 (2.0–4.4) 4.6 (2.8–5.3) p = 0.043
AUC0-12wks 34.3 (15.4–50.7) 49.3 (25.9–54.3) p = 0.043
AUC12-20wks 11.7 (4.5–25.9) 19.6 (5.2–30.3) p = 0.274
SHIV Plasma RNA
Peak 5.4 (3.1–6.0) 7.5 (6.5–8.9) p<0.0001
AUC0-12wks 37.7 (27.9–48.2) 57.9 (39.8–71.1) p = 0.0003
AUC12-20wks 12.7 (5.1–21.3) 17.2 (8.4–27.6) p = 0.159
doi:10.1371/journal.pone.0164821.t002
PrEP and SHIV DNA Reservoirs
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weeks of infectionwere also lower in the animals that received PrEP (AUC0-12wk of 34.3 com-
pared to 49.3 in controls; p = 0.043). (Table 2). However, DNA levels throughout weeks 12–20
were not significantly different from those seen in the control group (AUC12-20wk values of 11.7
and 19.6; p = 0.274) (Table 2). These results demonstrate a transient effect of PrEP on the SHIV
DNA reservoir that is not sustained during intermittent drug treatment and wanes over time. As
noted in previous studies [6, 8, 15], peak RNA levels and early acute RNA viremias (AUC0-12wk)
were also significantly lower in PrEP breakthrough infections compared to untreated infections
(p< 0.0001 and p = 0.0003, respectively, Table 2). The difference in RNA levels was not evident
throughout weeks 12–20, likely reflecting the low RNA set points that are generally achieved in
rhesus macaques infectedmucosally with SHIV162P3 (Table 2 and Fig 3).
We also evaluated if the overall SHIV DNA levels were related to the number of challenges
needed to infect a macaque. No significant correlation was found betweenAUC0-12wk or
AUC12-20wk values and cumulative number of virus challenges (Pearson correlation coefficients
of -0.128 (p = 0.61) and -0.384 (p = 0.115), respectively).
Long-term effect of PrEP on SHIV DNA levels in lymphoid tissues
We next investigated the effect of PrEP on the size of the virus reservoir in lymphoid tissues in
a late-stage of infection.We quantified cell-associated SHIV DNA in mesenteric, axillary, and
inguinal lymph nodes collected from 9 PrEP breakthrough and 8 placebo infections at nec-
ropsy. The specific PrEP interventions and dosing regimens, the length of treatment and time
Fig 3. Acute viral RNA and cell-associated DNA levels in macaques infected with SHIV162P3 while receiving
PrEP of placebo. The two top panels show plasma RNA levels in placebo and PrEP breakthrough infections, and
the two panels at the bottom show cell-associated DNA levels in PBMCs. Time 0 denotes peak viremia. The green
and red lines indicate median RNA or DNA levels, respectively. Horizontal dotted line denotes the limit of detection
of the SHIV RNA or DNA assays.
doi:10.1371/journal.pone.0164821.g003
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between SHIV infection and necropsy, and the levels of SHIV DNA for each lymph node loca-
tion are shown in Table 3. Because of limited specimen availability, only a few animals from
the first cohort were included in this second analysis. However, peak RNA viremias and AUC0-
12wk values in these additional PrEP breakthrough infections were also reduced compared to
untreated controls (p = 0.015 for each comparison).
Overall, SHIV DNA reservoirs in lymphoid tissues were similar in size among macaques
that received PrEP with FTC/TDF (median = 2.65 log10 SHIV DNA copies/106 cells;
range = 1.6–3.7) or placebo (median = 2.98; range = undetectable-4.4) (p = 0.34) (Fig 4). When
individual LN were analyzed, we found lower levels of SHIV DNA in axillary lymph nodes col-
lected from PrEP breakthrough infections (2.6 vs 3.2 DNA copies/106 cells in controls,
p = 0.02). Levels of SHIV DNA in inguinal and mesenteric lymph nodes were comparable
among the 2 groups of macaques (Table 3).
Discussion
We investigated in macaques if transient drug activity during PrEP breakthrough infection has
the potential to alter the pool of SHIV-infected cells. Our analysis includedmacaques that
received non-daily PrEP regimens with either FTC/TDF combination or TAF, and that contin-
ued receiving treatment with 1–2 weekly pills during several months. This scenario can easily
mimic newly acquired HIV-1 in persons receiving PrEP due to inconsistent adherence and
who continue on the PrEP regimen until diagnosis.We found that PrEP significantly reduced
Table 3. SHIV162P3 DNA levels in lymphoid tissues from PrEP breakthrough and placebo infections.
Log10 SHIV DNA copies/10
6 cells













G47 - - 6 3.1 2.8 2.9
A2E027 - - 6 3.4 3.3 3.2
A4E037 - - 6 4.4 n.a. 4.4
79R - - 17 3.1 3.0 2.9
19V - - 9 n.a. 0.7 0.7
AG65 - - 17 2.6 2.4 2.7
34F - - 18 3.5 3.2 3.6
RKZ7 - - 9 3.2 2.9 2.9
Median 9 3.2 2.9 2.9
FTC/TDF
1800 2 (-2h/+22h) 4.3 15 2.9 n.a. 3.0
DM91 2 (-2h/+22h) 4.3 16 3.1 3.0 n.a.
DL6V 2 (-22h/+2h) 3.8 16 0.7 2.6 2.4
FCW 2 (-24h/+24h) 6.5 10 0.7 1.8 1.6
DK40 2 (-3d/+2h) 5.0 11 2.6 2.3 2.5
34912 2 (-7d/+2h) 2.5 12 2.7 2.5 2.3
DL2T 1 (-3d) 3.8 8 1.6 0.7 1.6
35489 1 (-3d) 3.5 8 3.2 3.0 3.9
DK2R 1 (-3d) 3.5 6 n.a. n.a. 3.7
Median 3.7 11 2.6 2.5 2.5
p = 0.91 p = 0.02 p = 0.27 p = 0.44
n.a., not available
doi:10.1371/journal.pone.0164821.t003
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peak SHIV DNA levels in PBMCs, although the overall effect on the cell-associatedDNA reser-
voir was only transient and was lost during the first year of infection.Our findings differ from
studies of acute treatment with fully suppressive regimens which have generally observed sub-
stantial reductions in cell-associatedHIV or SIV DNA in PBMCs and lymphoid tissues [11–
14]. We surmise that antiretroviral drug activity when PrEP fails may not provide adequate
drug selective pressure to effectively reduce the pool of HIV-1-infected cells and result in post-
treatment virus control.
Our analysis was retrospective and included a heterogeneous group of macaques that
received FTC/TDF or TAF at different times relative to virus challenges. However, most of the
FTC/TDF failures received 2 weekly drug doses which is sufficient for accumulating TFV-DP
in PBMCs at levels above the prophylactic EC95 in macaques [21]. The dose of TAF given to
two of the animals was also sufficient to sustain high (>1000 fmols/106 cells) TFV-DP concen-
trations in PBMCs for up to 7 days [15]. Thus, although from different PrEP modalities, our
approach effectivelymodels transient antiviral drug activity that originates from failed PrEP
regimens during acute infection.
In contrast to persons who fail PrEP because of low medication adherence and drug levels,
our study included animals who represented rare PrEP failures that had drug concentrations in
PBMCs that were indistinguishable from protected animals [6, 7]. For instance, macaque
DK40 was the only animal infected during a two-dose FTC/TDF PrEP regimen that protected
5 other animals for a cumulative of 70 SHIV challenges [6]. Likewise,macaques 34912 and
35032 became infected while receiving an FTC/TDF regimen that decreased the risk of SHIV
infection by a factor of 9 [6]. Thus, the reductions in peak RNA and DNA levels seen in our
animals may not necessarily occur in HIV infections that are acquired due to low medication
Fig 4. SHIV162P3 DNA levels in lymphoid tissues collected from PrEP breakthrough infections and
untreated controls. Each individual point corresponds to the median SHIV DNA value observed in mesenteric,
axillary, and inguinal lymph nodes from one macaque. Overall SHIV DNA levels in FTC/TDF PrEP breakthrough
infections were not significantly different from those seen in placebo infections (p = 0.34). Horizontal lines are
median values observed in each group. Vertical lines are ranges.
doi:10.1371/journal.pone.0164821.g004
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adherence and substantially lower drug levels at the time of HIV acquisition. At later time
points after infection, continuous intermittent treatment with 1 or 2 weekly doses of FTC/TDF
or TAF effectivelymodels suboptimal drug adherence during undiagnosed infection, and was
the likely reason for the partial reductions in SHIV plasma viremia. Although viremias were
generally suppressed during the period of treatment, the replenishment of the cell-associated
SHIV DNA pool demonstrated expanded virus replication and seeding of virus reservoirs and,
thus, absence of post-treatment virus control despite the early reduction in virus replication.
Although not statistically significant, we found that the number of SHIV challenges required
to infect untreated macaques was smaller than those required to infect the animals that failed
PrEP, which raises questions about the effect of previous SHIV exposures on systemic control
of the virus post-infection. In a large retrospective analysis of 40 rhesus macaques exposed
repeatedly to SHIV162p3, we found no correlation between cumulative exposures to SHIV and
peak plasma RNA levels or AUC values [22]. In our study we also found no correlation
between cumulative SHIV exposures and SHIV DNA levels during the acute or the plateau
phase, suggesting that previous virus exposures have little or no impact on cell-associated
DNA levels in PBMCs.
The present study has several limitations. First, we did not address potential effects of PrEP
on the fraction of DNA genomes that are replication-competent. Reduced virus replication and
evolution due to PrEP might also result in more genetically homogeneous virus reservoirs or
favor preferential seeding of sequences with replication advantages in the presence of FTC or
TFV [8]. Second, we measured total cell-associatedDNA which includes unintegrated DNA
that may degrademore rapidly and contribute little to viral production. Also, we did not assess
reservoir distribution in cell subsets. In humans, early HAART is associated with lower infec-
tion rates of cell subsets with long life span as naïve and central memory T cells and a better
preservation of immune function [11, 23, 24]. Finally, although SHIV162p3 is easily transmissi-
ble at low doses and is thus well-suited for transmissibility studies, infections with this isolate
generally result in low set-point viremias compared to more pathogenic SIV isolates. Also, the
infection course is generally non-pathogenic [25, 26] which limits the ability to define long-
term effects of PrEP after treatment discontinuation.
In summary, we show that transient antiviral drug activity due to PrEP limits acute SHIV
replication but only has a transient effect on the size of the DNA reservoirs. These observations
suggest that suboptimal drug exposure in persons that are taking PrEP and become infected
with HIVmay not be sufficient to durably reduce the pool of HIV-1-infected cells and, there-
fore, not likely to predict good virus control post PrEP interruption.
Supporting Information
S1 Fig. Sensitivity and inter-assay variability of the DSP SHIV DNA assay. A) Serial dilu-
tions of SIV vP1 DNA plasmid were prepared in PBS and tested 10 times in the same run. The
assay consistently detected 10 copies of vp1. (B) Variability in Ct values observed in 16 separate
runs at different inputs of SIVmac239 vp1 plasmid and rhesus PBMCs. In all instances the %
coefficient of variation (CV) was<4%.
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